Lipid A is well known as being responsible for the expression of many of the biological activities: endotoxicity, adjuvanticity, antitumor activity and so on, of lipopolysaccharide (LPS) of gram-negative bacteria.
2) With the aim of enhancing its potentially beneficial immunostimulatory properties, numerous acyclic analogs related to lipid A partial structure have been synthesized.
3) We previously reported that N-tetradecanoyl-Lserine-linked lipid A analog (2) structurally similar to the lipid A disaccharide backbone exhibited potent mitogenic activity. 4) In addition, compound 3 with b-alanine introduced into compound 2 as a spacer possessed the same activity as 2. 5) Synthetic antigens generally have poor immunogenicity in the absence of immunological adjuvants. 6) However, the most popular adjuvant used in laboratory animals, Freund's complete adjuvant, is too toxic and unacceptable for humans. Therefore, development of totally synthetic vaccines against cancers or human immunodeficiency virus (HIV) using the synthetic immunoadjuvants, N-acetyl-muramyl-L-alanyl-Disoglutamine (MDP) and lipopeptide analog, has been attempted. 7) One of the merits of synthetic vaccines is that they are safer and more versatile than a whole or viral protein vaccine. We recently have reported the development of completely synthetic vaccines (4, 5) against cancers which consist of the lipid A analog (3) as a synthetic immunoadjuvant , covalently coupled to Tn (a-D-GalNAc-(1→O)-Ser) and Sialyl Tn (a-D-Neu5Ac-(2→6)-a-D-GalNAc-(1→O)-Ser) epi-topes for antigens without the addition of other macromolecular carriers or adjuvants, respectively. 8) In this paper, we describe the synthesis of conjugates 6 and 7 containing of cancer peptide antigens, identified as tumour-associated peptide antigens on the surface of cancer cells, covalently attached to a N-tetradecanoyl-L-seryl-b-alanine-containing D-glucosamine derivative (3) structurally similar to lipid A, and their biological effects.
Synthesis First, synthesis of leukemia cancer gene derived peptide antigen derivative (8) 9) and melanoma MAGE-3 derived peptide epitope (9) 10) was accomplished manually by a stepwise liquid-phase procedure shown in Charts 1 and 2, respectively.
The assembly of the synthetic adjuvant-cancer peptide antigen conjugates is shown in Chart 3. Compound 3 was coupled with p-nitrophenol in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCl) in N,N-dimethylformamide (DMF) to give the p-nitrophenyl ester (10) [FAB-MS m/z: 1106 (MϩH) ϩ , 1128 (MϩNa) ϩ ] in 55% yield. The active ester (10) was condensed with 8 and 9 in the presence of diisopropylethylamine (DIEA) to give 6 [FAB-MS m/z: 1797 (MϩNa) ϩ ] and 7 [FAB-MS m/z: 2030 (MϩNa) ϩ ] in 69% and 35%, respectively, after purification by chromatography on a column of silica gel and then Sephadex LH-20, followed by lyophilization from H 2 O suspension.
Biological Activity In a preliminary examination of mitogenic activities towards the splenocytes of C3H/He mice, 11) conjugates 6 and 7 exhibited potent mitogenic activities in comparison with lipid A analog 3 (Fig. 3.) . It is speculated that lipid A conjugates 6 and 7 may amplify peptide antigenspecific immune responses in mice. 
Experimental
All melting points are uncorrected. Optical rotations were measured with a JASCO DIP-140 digital polarimeter. IR spectra were recorded on a JASCO IR-810 spectrometer.
1 H NMR spectra were recorded with a JEOL JNM-EX 270 (270 MHz) spectrometer.
1 H chemical shifts are given in ppm relative to Me 4 Si (dϭ0) in CDCl 3 or CD 3 OD as internal standards at ambient temperature. The abbreviations of signal patterns are as follows: s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Fast atom bombardment (FAB) mass spectra were obtained with a JEOL JMS SX-102 mass spectrometer in the positive ion mode using NBA matrix. Column chromatography was performed on Silica Gel 60 (70-230 mesh, Merck) and Sephadex LH-20 (Pharmacia). Thin-layer chromatography (TLC) was performed on aluminum sheets coated with Silica Gel 60F 254 (Merck). The spots were visualized by spraying the plates with 5% aqueous sulfuric acid in MeOH and then heating.
N-tert-Butoxycarbonyl-O-benzyl-L-seryl-L-leucine Benzyl Ester (11) To a solution of L-leucine benzyl ester p-toluenesulfonate (2.00 g, 5.08 mmol), N-methylmorpholine (NMM) (0.52 g, 5.08 mmol), tert-butoxycarbonyl-O-benzyl-L-serine (1.50 g, 5. 08 mmol) and 1-hydroxybenzotriazole (HOBt) (0.78 g, 5.08 mmol) in DMF (10 ml) were added EDCl (0.98 g, 5.08 mmol) and NMM (0.52 g, 5.08 mmol) at 0°C and the mixture was stirred for 18 h at room temperature under argon. After removal of the solvent, the residue was dissolved in CH 2 Cl 2 and washed with saturated aqueous NaHCO 3 ,10% aqueous citric acid and saturated aqueous NaCl, dried over anhydrous MgSO 4 and concentrated. The residue was purified by silica gel column chromatography (hexane- : C, 66.75; H, 8.07; N, 6.87. Found: C, 66.71; H, 8.12; N, 6.98 .
L-Leucyl-O-benzyl-L-seryl-L-leucine Benzyl Ester Hydrochloride (14) The reaction was carried out using 13 (2.30 g, 3.76 mmol) in a manner similar to the preparation of 12 to give amorphous 14 (2.06 g, quant.), which was used for the subsequent condensation without further purification.
The reaction was carried out using 14 (2.06 g, 3.76 mmol) and tert-butoxycarbonyl-L-proline (0.89 g, 4.13 mmol) in a manner similar to the preparation of 11 to give 15 (2.46 g, 92%), after purification by silica gel column chromatography (hexane-EtOAc 1 : 3 , 7.96; N, 7.90. Found: C, 65.90; H, 8.12; N, 7.61 .
L-Prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine Benzyl Ester Hydrochloride (16)
The reaction was carried out using 15 (2.36 g, 3.33 mmol) in a manner similar to the preparation of 12 to give amorphous 16 (2.01 g, 94%), which was used for the subsequent condensation without further purification. 3.12 mmol) and tert-butoxycarbonyl-L-leucine H 2 O (0.85 g, 3.43 mmol) in a manner similar to the preparation of 11 to give amorphous 17 (2.30 g, 90%), after purification by silica gel column chromatography (CH 2 Cl 2 - 
Benzyl Ester Hydrochloride (18) The reaction was carried out using 17 (2.22 g, 2.70 mmol) in a manner similar to the preparation of 12 to give amorphous 18 (2.05 g, quant.), which was used for the subsequent condensation without further purification. 
Glycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine Benzyl Ester Hydrochloride (20)
The reaction was carried out using 19 (2.15 g, 2.45 mmol) in a manner similar to the preparation of 12 to give amorphous 20 (2.00 g, quant.), which was used for the subsequent condensation without further purification. C, 62.82; H, 8.01; N, 9.86. Found: C, 62.96; H, 7.88; N, 9.77 .
Benzyl Ester Hydrochloride (22) The reaction was carried out using 21 (1.60 g, 1.64 mmol) in a manner similar to the preparation of 12 to give amorphous 22 (1.50 g, quant.), which was used for the subsequent condensation without further purification. , 8.19; N, 10.11. Found: C, 62.68; H, 8.08 ; N, 10.00.
L-leucine Hydrochloride (8) Compound 23 (0.23 g, 0.21 mmol) was treated with 4 N HCl-dioxane (10 ml) in a manner similar to the preparation of 12 to give the amino compound which was dissolved in EtOH (25 ml) and then was hydrogenated over Pd(OH) 2 -C (0.10 g) for 6 h at 40°C, then filtered and concentrated. The residue was purified by reverse phase high performance liquid chromatography (RP-HPLC) purification (column: Asahipak ODP-50 (0.6ϫ25 cm). Eluent: A, 0.05% trifluoroacetic acid (TFA); B, CH 3 CN, linear gradient from 25% to 45% B in 30 min. Detection: UV at 210 nm. Flow rate: 1.0 ml/min) to give amorphous 6 (0.155 g, 89%), 
L-Leucyl-O-benzyl-L-tyrosine Benzyl Ester Hydrochloride (27)
The reaction was carried out by using 26 (0.80 g,1.39 mmol) in a manner similar to the preparation of 12 to give amorphous 27 (0.71 g, quant.), which was used for the subsequent condensation without further purification.
N a a -tert-Butoxycarbonyl-N im -2,4-dinitrophenyl-L-histidyl-L-leucyl-Obenzyl-L-tyrosine Benzyl Ester (28)
The reaction was carried out using 27 (0.71 g, 1.39 mmol) and tert-butoxycarbonyl-N im -2,4-dinitrophenyl-L-histidine. isopropyl amine · isopropanol (IPA) (0.67 g, 1.39 mmol) in a manner similar to the preparation of 11 to give amorphous 28 (1.10 g, 90%), after purification by silica gel column chromatography (CH 2 Cl 2 - , 5.91; N, 11.05. Found: C, 62.52; H, 5.92; N, 10.97 .
N im -2,4-Dinitrophenyl-L-histidyl-L-leucyl-O-benzyl-L-tyrosine Benzyl Ester Hydrochloride (29)
The reaction was carried out using 28 (1.00 g, 1.14 mmol) in a manner similar to the preparation of 12 to give amorphous 29 (0.93 g, quant.), which was used for the subsequent condensation without further purification. N a a -tert-Butoxycarbonylglycyl-N im -2,4-dinitrophenyl-L-histidyl-Lleucyl-O-benzyl-L-tyrosine Benzyl Ester (30) The reaction was carried out using 29 (0.93 g, 1.14 mmol) and tert-butoxycarbonylglycine (0.20 g, 1.14 mmol) in a manner similar to the preparation of 11 to give amorphous 30 (0.94 g, 88%), after purification by silica gel column chromatography (CH 2 Cl 2 - , 5.92; N, 11.76. Found: C, 60.56; H, 5.75; N, 11.55 .
Glycyl-N im -2,4-dinitrophenyl-L-histidyl-L-leucyl-O-benzyl-L-tyrosine Benzyl Ester Hydrochloride (31)
The reaction was carried out using 30 (0.84 g, 0.90 mmol) in a manner similar to the preparation of 12 to give 31 (0.78 g, quant.) as amorphous powder, which was used for the subsequent condensation without further purification. , 6.37; N, 11.72. Found: C, 60.49; H, 6.11; N, 11.57 .
L-tyrosine Benzyl Ester Hydrochloride (33) The reaction was carried out using 32 (0.75 g, 0.72 mmol) in a manner similar to the preparation of 12 to give amorphous 33 (0.70 g, quant.), which was used for the subsequent condensation without further purification. , 60.64; H, 6.32; N, 11.11. Found: C, 60.62; H, 6.21; N, 10.94 .
Benzyl Ester Hydrochloride (37) The reaction was carried out using 36 (0.56 g, 0.42 mmol) in a manner similar to the preparation of 11 to give amorphous 37 (0.53 g, quant.), which was used for the subsequent condensation without further purification. O: C, 60.64; H, 6.51; N, 11.31. Found: C, 60.38; H, 6.34; N, 11.10 .
Benzyl Ester Hydrochloride (39) The reaction was carried out using 38 (0.44 g, 0.30 mmol) in a manner similar to the preparation of 12 to give amorphous 39 (0.42 g, quant.), which was used for the subsequent condensation without further purification. 6.42; N, 10.74. Found: C, 61.61; H, 6.44; N, 10.46 .
A solution of compound 40 (0.19 g, 0.11 mmol) in 10% PhSH-DMF (3 ml) was stirred for 4 h at room temperature. After removal of the solvent, the residue was crystallized from ether to give yellow amorphous 41 (0.165 g, 96%) .
The reaction was carried out using 41 (0.165 g, 0.11 mmol) in a manner similar to the preparation of 12 to give amorphous 42 (0.16 g, quant.), which was used for the subsequent condensation without further purification. 
N-Tetradecanoyl-O-[2-deoxy-2-[(R)-3-tetradecanoyloxytetradecanoylamino]-b b-D-glucopyranosyl]-L-seryl-b b-alanine p-Nitrophenyl Ester (10)
To a solution of 3 (31 mg, 0.031 mmol) and p-nitrophenol (31 mg, 0.22 mmol) in DMF (4 ml) cooled to 0°C was added EDCl (31 mg, 0.16 mmol), and the mixture was stirred for 16 h at room temperature. The mixture was poured into H 2 O (3 ml), the insoluble materials were collected by filtration and dried. This product was purified by silica gel column chromatography using CH 2 Cl 2 -MeOH (20 : 1) to give 10 (18 mg, 53%) as a yellow solid.
[a] D Ϫ18.4°(cϭ0.22, CHCl 3 ). The reaction was carried out using 9 (6 mg, 0.006 mmol), 10 (8 mg, 0.007 mmol) and DIEA (10 mg, 0.08 mmol) in a manner similar to the preparation of 6 to give amorphous 7 (4 mg, 35%), after purification by silica gel column chromatography (CH 
